NASDAQ:INVA Innoviva Q4 2024 Earnings Report $20.74 +0.08 (+0.39%) Closing price 09/25/2026 04:00 PM EasternExtended Trading$20.74 0.00 (0.00%) As of 09/25/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Innoviva EPS ResultsActual EPS$0.57Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AInnoviva Revenue ResultsActual Revenue$91.81 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AInnoviva Announcement DetailsQuarterQ4 2024Date2/26/2025TimeAfter Market ClosesConference Call DateWednesday, February 26, 2025Conference Call Time4:00PM ETUpcoming EarningsInnoviva's Q3 2026 earnings is estimated for Wednesday, November 4, 2026, based on past reporting schedules, with a conference call scheduled on Thursday, November 5, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Annual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Annual report(10-K) Innoviva Earnings HeadlinesInnoviva (NASDAQ:INVA) Stock Picked Up by Analysts at OppenheimerSeptember 25 at 1:54 AM | americanbankingnews.comTheravance Biopharma Completes Merger and Plans Nasdaq DelistingSeptember 23, 2026 | tipranks.comLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top S&P 500 stock for 12 years running—and today, he's giving away his #1 AI stock pick for 2026, free. This company's sales are up 28% year over year, it holds over 30,000 patents in wireless and video technology, and it just earned an A-rating in his proprietary Stock Grader system that has cost him $9 million to build and maintain. | InvestorPlace (Ad)Zymeworks Closes Theravance Acquisition and CVR FinancingSeptember 23, 2026 | tipranks.comOppenheimer Upgrades Innoviva to Outperform From Neutral, $35 Price TargetSeptember 23, 2026 | marketscreener.comMTheravance Biopharma issues disclosures amid Zymeworks mergerSeptember 10, 2026 | tipranks.comSee More Innoviva Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Innoviva? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Innoviva and other key companies, straight to your email. Email Address About InnovivaInnoviva (NASDAQ:INVA) is a biopharmaceutical company focused on developing and commercializing healthcare products through strategic partnerships, royalty arrangements and investments in biotechnology businesses. The company’s portfolio has historically centered on respiratory medicines, with rights connected to products developed with GlaxoSmithKline, including Trelegy Ellipta, Anoro Ellipta and Breo Ellipta. Innoviva generally operates as an asset-focused healthcare company rather than as a traditional commercial pharmaceutical manufacturer. It receives royalties and other economic benefits from partnered products marketed in multiple international markets, while pursuing additional opportunities in biopharmaceutical and healthcare companies. Its portfolio has also included an investment in Armata Pharmaceuticals, which is developing bacteriophage-based therapies intended to treat drug-resistant bacterial infections. The company was previously known as Theravance, Inc. and adopted the Innoviva name in 2016 as its business evolved toward a royalty and strategic-investment model. Innoviva is headquartered in the United States and relies substantially on partners and affiliated companies for the development, regulatory approval and commercialization of its products. Pavel Raifeld serves as the company’s chief executive officer.View Innoviva ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 09/21 - 09/25Costco Ends Its Fiscal Year on a High Note, Eyes Big ExpansionCracker Barrel Stock Is Rallying Again, But the Turnaround Still Has a Traffic ProblemDarden Restaurants Serves Up Fresh Catalysts for a Stock Price RallySoFi Is Bypassing the Banking Bottleneck With Stablecoin SettlementSuper Micro’s Vera Rubin Shipments Put Its AI Infrastructure Advantage to the TestHims & Hers Slides Nearly 7% as Legal Pressure Adds to Its Growing List of Risks Upcoming Earnings Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
